Fast and safe : Optimising multiple sclerosis infusions during COVID-19 pandemic

Journal article


Rath, Louise, Bui, Minh Viet, Ellis, Julian, Carey, John, Baker, Josephine, Taylor, Lisa, Fernando, Hasini, Taylor, Nicola, Savage, Poppy, Richards, Janene, Zhong, Michael, Kalincik, Tomas, Skibina, Olga, Wesselingh, Robb, Nguyen, Ai-Lan, Monif, Mastura, Butzkueven, Helmut and van der Walt, Anneke. (2021). Fast and safe : Optimising multiple sclerosis infusions during COVID-19 pandemic. Multiple Sclerosis and Related Disorders. 47, p. Article 102642. https://doi.org/10.1016/j.msard.2020.102642
AuthorsRath, Louise, Bui, Minh Viet, Ellis, Julian, Carey, John, Baker, Josephine, Taylor, Lisa, Fernando, Hasini, Taylor, Nicola, Savage, Poppy, Richards, Janene, Zhong, Michael, Kalincik, Tomas, Skibina, Olga, Wesselingh, Robb, Nguyen, Ai-Lan, Monif, Mastura, Butzkueven, Helmut and van der Walt, Anneke
Abstract

Background: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients.

Objective: To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic.

Methods: Patients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed.

Results: We analysed 269 rapid natalizumab infusions and 100 rapid ocrelizumab infusions. Infusion related reactions during the natalizumab or ocrelizumab infusions occurred in two patients (1.52%) and eight patients (8%), respectively. All infusion related reactions were mild to moderate and did not require infusion discontinuation. No infusion reactions occurred during the post-infusion observation. Patient experience was positive.

Conclusion: Frequency or severity of infusion related reactions in rapid infusions were no different compared to published data. In the setting of COVID-19, pandemic rapid infusion protocols could potentially save hospital resources and limit patient exposure to a high-risk clinical setting while still maintaining ongoing treatment of multiple sclerosis.

Keywordsmultiple sclerosis; COVID-19 pandemic; resource utilisation; infusion related reactions; rapid infusions; natalizumab; ocrelizumab; post observational time
Year2021
JournalMultiple Sclerosis and Related Disorders
Journal citation47, p. Article 102642
PublisherElsevier B.V.
ISSN2211-0348
Digital Object Identifier (DOI)https://doi.org/10.1016/j.msard.2020.102642
Scopus EID2-s2.0-85097684292
Page range1-6
Publisher's version
License
All rights reserved
File Access Level
Controlled
Output statusPublished
Publication dates
Online01 Dec 2020
Publication process dates
Accepted22 Nov 2020
Deposited01 Dec 2022
Permalink -

https://acuresearchbank.acu.edu.au/item/8y826/fast-and-safe-optimising-multiple-sclerosis-infusions-during-covid-19-pandemic

Restricted files

Publisher's version

  • 29
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as

Related outputs

Protocol for a mixed methods process evaluation of the Promoting Resilience in Nurses (PRiN) trial
Bui, Minh, McInnes, Elizabeth, Ennis, Gary and Foster, Kim. (2022). Protocol for a mixed methods process evaluation of the Promoting Resilience in Nurses (PRiN) trial. International Journal of Mental Health Nursing. 31(3), pp. 687-696. https://doi.org/10.1111/inm.12989